We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Vapourtec Unveils Peptide-Builder

A benchtop peptide synthesiser.
Credit: Vapourtec.
Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Flow chemistry specialists Vapourtec have developed the Peptide-Builder, a fully automated, high throughput, benchtop peptide synthesiser, which was launched at the recent TIDES Europe event in Hamburg.


Incorporating Vapourtec’s disruptive Variable Bed Flow Reactor (VBFR) technology, it dramatically improves cycle efficiency and reduces solvent consumption.


Based on customer feedback, the Peptide-Builder is designed to be the smallest high throughput synthesiser available, delivering more peptides per square meter of lab space, whilst keeping reagent consumption low.

Want more breaking news?

Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.

Subscribe for FREE

The flexible scale of the synthesiser ranges from 0.05 mmol to 1 mmol and is compatible with any type of resin.


Operating in a sequential way, one GLP-1 analogue can be synthesized in under four hours and 16 analogues over a weekend.


Vapourtec’s Dr Manuel Nuño explained: “This new synthesizer features intuitive software developed in collaboration with major pharma companies. Just type the sequence and amount of resin, press ‘run’ and walk away.”


The technology ensures minimal consumption of reagents (< 3 equivalents of AA) and solvents (< 80 ml / mmol / cycle) and provides rapid and efficient solvent exchange enabling automated addition of side chains.


Unique insights into synthesis, including detailed analysis of aggregation events and quantification of Fmoc group removal, are provided in a report at the conclusion of synthesis.


“The disruptive VBFR technology makes this synthesiser a game-changer for peptide synthesis by improving efficiency, optimising workflows and reducing space requirements,” concluded Manuel.